[go: up one dir, main page]

MX2022005502A - Purificacion de proteinas. - Google Patents

Purificacion de proteinas.

Info

Publication number
MX2022005502A
MX2022005502A MX2022005502A MX2022005502A MX2022005502A MX 2022005502 A MX2022005502 A MX 2022005502A MX 2022005502 A MX2022005502 A MX 2022005502A MX 2022005502 A MX2022005502 A MX 2022005502A MX 2022005502 A MX2022005502 A MX 2022005502A
Authority
MX
Mexico
Prior art keywords
protein purification
purification
protein
biotherapeutics
vaccines
Prior art date
Application number
MX2022005502A
Other languages
English (en)
Inventor
Brian Polilli
Christopher Rode
John Schreffler
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2022005502A publication Critical patent/MX2022005502A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se describe un proceso para la purificación de proteínas, concretamente un proceso para la purificación de una glucoproteína, tal como una proteína de la envoltura del VIH, útil para vacunas o productos bioterapéuticos.
MX2022005502A 2019-11-07 2020-11-06 Purificacion de proteinas. MX2022005502A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932180P 2019-11-07 2019-11-07
US202063105664P 2020-10-26 2020-10-26
PCT/EP2020/081271 WO2021089770A2 (en) 2019-11-07 2020-11-06 Protein purification

Publications (1)

Publication Number Publication Date
MX2022005502A true MX2022005502A (es) 2022-06-02

Family

ID=73198294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005502A MX2022005502A (es) 2019-11-07 2020-11-06 Purificacion de proteinas.

Country Status (11)

Country Link
US (1) US11857619B2 (es)
EP (1) EP4054629A2 (es)
JP (1) JP7170942B1 (es)
KR (1) KR20220092896A (es)
CN (1) CN114585639A (es)
AU (1) AU2020381082B2 (es)
BR (1) BR112022007929A2 (es)
CA (1) CA3159907A1 (es)
IL (1) IL292760A (es)
MX (1) MX2022005502A (es)
WO (1) WO2021089770A2 (es)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1433851A3 (en) * 1998-12-31 2004-10-13 Chiron Corporation Improved expression of HIV polypeptides and production of virus-like particles
WO2007146197A1 (en) * 2006-06-09 2007-12-21 Xing-Xiang Li Methods and reagents for virus isolation and detection
WO2007149490A1 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins
US9005631B2 (en) * 2008-08-04 2015-04-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Membrane proximal region of HIV gp41 anchored to the lipid layer of a virus-like particle vaccine
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
CA2789564C (en) * 2010-03-10 2019-08-13 F. Hoffmann-La Roche Ag Method for purifying immunoglobulin solutions
US9932370B2 (en) 2013-01-07 2018-04-03 Beth Israel Deaconess Medical Center, Inc. Stabilized mosaic human immunodeficiency virus type 1 (HIV-1) GP140 envelope (ENV) trimers
KR102382662B1 (ko) * 2013-07-01 2022-04-06 체에스엘 베링 아게 방법
CN103992396B (zh) * 2014-04-17 2017-03-29 南开大学 一种潜在的高效重组HIV‑1 CRF07‑BC gp140免疫原的制备方法
US10526583B2 (en) * 2014-07-02 2020-01-07 University Of Florida Research Foundation, Incorporated Compositions and methods for purifying recombinant adeno-associated virus
MX377967B (es) * 2014-09-26 2025-03-10 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por virus de inmunodeficiencia humana.
WO2016073401A1 (en) * 2014-11-03 2016-05-12 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
US9580477B2 (en) * 2015-03-16 2017-02-28 The Catholic University Of America Approach to produce HIV-1 GP140 envelope protein trimers
WO2017102929A1 (en) 2015-12-15 2017-06-22 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
JP7046832B2 (ja) * 2016-05-02 2022-04-04 ザ スクリプス リサーチ インスティテュート Ｈｉｖ－１免疫原に関連した組成物および方法
SG11201810549TA (en) * 2016-06-16 2018-12-28 Janssen Vaccines & Prevention Bv Hiv vaccine formulation
CN110891601A (zh) * 2017-07-19 2020-03-17 扬森疫苗与预防公司 三聚体稳定性hiv包膜蛋白突变
US20220041650A1 (en) * 2018-12-03 2022-02-10 Duke University Purification method for recombinant proteins and nanoparticles

Also Published As

Publication number Publication date
CA3159907A1 (en) 2021-05-14
JP2022547341A (ja) 2022-11-11
BR112022007929A2 (pt) 2022-07-12
WO2021089770A3 (en) 2021-07-01
US20210138060A1 (en) 2021-05-13
JP7170942B1 (ja) 2022-11-14
WO2021089770A2 (en) 2021-05-14
CN114585639A (zh) 2022-06-03
IL292760A (en) 2022-07-01
EP4054629A2 (en) 2022-09-14
AU2020381082B2 (en) 2022-09-22
KR20220092896A (ko) 2022-07-04
AU2020381082A1 (en) 2022-04-28
US11857619B2 (en) 2024-01-02

Similar Documents

Publication Publication Date Title
WO2022221335A8 (en) Respiratory virus combination vaccines
MX2021015894A (es) Peptidos acetales para estabilizar enzimas.
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
PH12021551315A1 (en) Achromosomal dynamic active systems
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PH12021552176A1 (en) Antibodies and methods for treatment of influenza a infection
CA3048452C (en) Processes for preparing glycoprotein-drug conjugates
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
EP4424373A3 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
PH12020500042A1 (en) Method for preparing influenza working virus seed stock, method for preparing influenza vaccine using same seed stock, and virus seed stock prepared by same method
MX2020004093A (es) Puzolana de vidrio activada.
MX2022005502A (es) Purificacion de proteinas.
MX2022006005A (es) Metodo para producir virus de la influenza reagrupados.
MX2024013042A (es) Compuestos para el tratamiento de la infeccion por arenavirus.
MX2021008323A (es) Preparacion de 5-aril pentanoles.
MX2020010348A (es) Proceso para la fermentacion de ascomycota.
WO2018029383A8 (de) Infektiöse bronchitis (ib)-virus varianten und diesbezügliche zusammensetzungen, verwendungen und verfahren
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
WO2021226037A8 (en) Treatment of viral infections
WO2020128020A3 (de) Verfahren zur herstellung von 2-alkoxy-4-amino-5-methyl-pyridinen und/oder von 2-alkoxy-4-alkylamino-5-methyl-pyridinen
AU2019248350A8 (en) Process for making sarecycline hydrochloride
MX2020010343A (es) Proceso para la purificacion de biocomposiciones complejas.
WO2018198101A3 (en) Processes for the preparation of crystalline form of eluxadoline
WO2019014286A3 (en) IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF